Pulse Electronics Corporation Common Stock PULS 深 沪
等待开盘 09-23 09:30:00 美东时间
49.79
+0.020
+0.04%
华盛通- 最 高49.79
- 今 开49.79
- 成交量 207.68万股
- 最 低 49.78
- 昨 收 49.77
- 总市值 115.51亿
- 52周最高 49.79
- 市盈率 静 --
- 换手率 0.00%
- 52周最低 47.3329
- 委 比 67.67%
- 总股本 2.32亿
- 历史最高 49.79
- 量 比 1.15
- 振 幅 0.02%
- 历史最低 37.4711
- 每 手 1
- 风险率 0.71%
个股概要
财务分析
公司资料
相关新闻
分红派息
- 分时图
- 日k
- 周k
- 月k
相关新闻
更多Pendle 收益策略全景解读：Pulse的AgentFi新范式
Pendle作为DeFi领域中首个专注于收益率拆分与交易的协议，通过创新的PT/YT代币机制，成功构建了收益型资产的“价格发现场所”，为加密资产的“收益率曲线”提供二级市场交易支持。其收益拆分机制将带收益的基础资产拆分为本金代币（PT）和收益代币（YT），用户可以通过PT锁定固定收益或通过YT进行收益投机和跨期套利。 在市场周期变化中，Pendle提供了差异化的策略，以满足不同风险偏好投资者的需求。牛市初期适合押注收益率上升，牛市亢奋期和熊市则更适合通过买入PT锁定高利率或在低利率环境下保值。震荡市时，跨期套利策略更具优势。 此外，Pendle还推出了Boros模块，将资金费率资产化，引入利率掉期、基差交易等传统金融衍生品工具，进一步丰富了策略维度。Pulse作为首个基于Pendle PT策略的AgentFi产品，实现了跨链固定收益场景的自动化优化，通过智能调仓和再平衡，最大化资金利用率和收益。
09-10 07:28
Novartis Sees Hope In Reducing Lifelong Treatment Burden For Autoimmune Blood Disorder
Novartis' ianalumab plus eltrombopag significantly extended treatment response and improved platelet counts in a Phase 3 immune thrombocytopenia trial.
08-12 21:43
Boston Scientific Reports Higher Profit Margins In Q2, Lifts Guidance
Boston Scientific beats Q2 estimates, posts 22.8% revenue growth, and raises full-year outlook on strong cardiovascular and MedSurg performance.
07-23 22:22
Novartis' Cosentyx Fails Late-Stage Giant Cell Arteritis Trial
Cosentyx missed its main goal in a Phase 3 GCA study, but showed lower steroid use. Novartis plans full review of the trial data.
07-03 21:00
Novartis' Fabhalta Delivers Hemoglobin Gains, Reduces Fatigue In Patients With Rare Blood Disorder
Novartis' Fabhalta improved hemoglobin, reduced fatigue and eliminated transfusion need in a Phase 3B PNH study presented at the 2025 EHA Congress.
06-13 02:25
首款阿尔茨海默病血液检测产品获FDA批准，开发商称下月在美上市
①美国FDA上周批准首款用于诊断阿尔茨海默病的检测试剂； ②检测过程便捷微创，费用仅为PET的一小部分，预计今年6月下旬在美国推出，并计划在多国提交审批。
05-20 21:30
Merck Presents New Clinical And Outcomes Research Data On Pulmonary Arterial Hypertension At ATS 2025 International Conference
Preliminary results from a pooled analysis of clinical trial data evaluating the long-term safety and favorable benefit-risk profile of WINREVAIR™ to be featured as a late-breaking presentationMerck (NYSE:MRK),
05-16 18:47
EPIC Suisse Inaugurates PULSE: A Sustainable Hub in Health Valley
EPIC Suisse Ltd. ( ($CH:EPIC) ) has issued an update. EPIC Suisse AG has inaugu...
05-16 13:32
Pulsar Group PLC Sees Increase in Major Holdings
Access Intelligence ( ($GB:PULS) ) just unveiled an announcement. Pulsar Group ...
05-13 19:22
Pulsar Group PLC to Raise £3 Million Through Share Placing
Access Intelligence ( ($GB:PULS) ) has issued an announcement. Pulsar Group PLC...
05-07 23:42
